Dana Casey

Dr. Dana Casey


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2019 in Cancer
Verified
Journal Article
Open access
PDF file
DCDana Casey
Dana Casey
YCYueh‐Yun Chi
Yueh‐Yun Chi
SDSarah S. Donaldson
Sarah S. Donaldson
DHDouglas S. Hawkins
Douglas S. Hawkins
JTJing Tian
Jing Tian
SWSuzanne L. Wolden
Suzanne L. Wolden
Background: The objective of this study was to evaluate local control for patients with intermediate‐risk rhabdomyosarcoma (RMS) treated on Children's Oncology Group (COG) protocol ARST0531.Methods: This study analyzed 424 patients with intermediate‐risk RMS. Patients were randomized to chemotherapy with either vincristine, dactinomycin, and cyclophosphamide (VAC) or VAC alternating with vincristine and irinotecan. With the goal of improving local control, radiation therapy (RT) was delivered early at week 4 and was concurrent with irinotecan in the experimental arm. Individualized local control plans for children 24 months old or younger were allowed. Local failure on ARST0531 was compared with local failure on the preceding COG intermediate‐risk study, D9803.Results: For patients with group I/II alveolar RMS (n = 55), the 5‐year cumulative incidence of local failure was 13.4%; for group III alveolar RMS (n = 141), it was 20.2%; and for group III embryonal RMS (n = 228), it was 27.9% (P = .03). Among patients with group III disease, local failure did not differ by histology, site, nodal status, RT modality, or treatment arm. Local failure was worse for a tumor size >5 cm (32.3% vs 16.7%; P = .001). Among patients with group III embryonal RMS, local failure was higher on ARST0531 than D9803 (27.9% vs 19.4%; P = .03). After the exclusion of patients 24 months old or younger or patients who did not receive radiation, local failure remained significantly increased on ARST0531 (P = .02). After adjustments for clinical prognostic factors, event‐free survival and overall survival were worse on ARST0531 (P = .004 and P = .05, respectively).Conclusions: Despite interventions designed to enhance local control, local control was inferior on ARST0531 in comparison with D9803. The reason for this is unclear, but it could be the reduced cyclophosphamide dose on ARST0531.

20 May 2021 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
DCDana Casey
Dana Casey
KPKenneth L. Pitter
Kenneth L. Pitter
LWLeonard H. Wexler
Leonard H. Wexler
ESEmily K. Slotkin
Emily K. Slotkin
GGGaorav P. Gupta
Gaorav P. Gupta
SWSuzanne L. Wolden
Suzanne L. Wolden

20 October 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
TLTimothy B. Lautz
Timothy B. Lautz
YCYueh‐Yun Chi
Yueh‐Yun Chi
MLMinjie Li
Minjie Li
SWSuzanne L. Wolden
Suzanne L. Wolden
DCDana Casey
Dana Casey
DRDavid A. Rodeberg
David A. Rodeberg

29 September 2023 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
DCDana Casey
Dana Casey
IVIvan R. Vogelius
Ivan R. Vogelius
NBN. Patrik Brodin
N. Patrik Brodin
KRKenneth B. Roberts
Kenneth B. Roberts
MAMichele Avanzo
Michele Avanzo
AOArthur Olch
Arthur Olch

6 February 2023 in Cancer Medicine
Verified
Journal Article
Open access
MSMonika Sparber-Sauer
Monika Sparber-Sauer
AFAndrea Ferrari
Andrea Ferrari
SSSheri L. Spunt
Sheri L. Spunt
CVChristian Vokuhl
Christian Vokuhl
DCDana Casey
Dana Casey
DODaniel Orbach
Daniel Orbach
Background: Margin status following surgery in children, adolescents, and young adults with soft tissue sarcomas is controversial and has been defined differently by various specialties, with definitions changing over time and by cooperative group. The International Soft Tissue Sarcoma Consortium (INSTRuCT) is a collaboration of the Children's Oncology Group (COG) Soft Tissue Sarcoma Committee, European pediatric Soft Tissue sarcoma Study Group (EpSSG), and the European Cooperative Weichteilsarkom Studiengruppe (CWS) devoted to improving patient outcomes by pooling and mining cooperative group clinical trial data.Methods: The INSTRuCT non‐rhabdomyosarcoma soft tissue sarcoma (NRSTS) working group aimed to develop international harmonized recommendations regarding surgical margin assessment and definitions in children and adolescents with soft tissue tumors.Results and Conclusion: This review addresses accepted principles and areas of controversy, including the perspectives of surgeons, pathologists, radiation oncologists, and pediatric oncologists, to develop a framework for building common guidelines for future research.

29 April 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
DCDana Casey
Dana Casey
HMHenry Mandeville
Henry Mandeville
JBJulie A. Bradley
Julie A. Bradley
SHSimone A. J. Ter Horst
Simone A. J. Ter Horst
ASAnthony Sheyn
Anthony Sheyn
SWSuzanne L. Wolden
Suzanne L. Wolden